Journals / Gülhane Tıp Dergisi / 2014 / Cilt: 56 - Sayı: 3

The effect of scoring systems for predicting locoregional recurrence in patients with differentiated thyroid cancer

Diferansiye Tiroid Kanserli Hastalarda Skorlama Sistemlerinin Lokal Nüksü Öngörü Değeri

Pages
138–142
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Scoring systems may be helpful in predicting locoregional recurrence and thus patients who will benefit from adjuvant therapy can be determined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The effect of scoring systems for predicting locoregional recurrence in patients with differentiated thyroid cancerDifferentiated thyroid cancer constitutes approximately 90% of all thyroid tumors.
📊
Key Findings & Data:Despite the excellent prognosis in the majority of patients, recurrence rates remain high.
💡
Conclusion & Impact:Scoring systems may be helpful in predicting locoregional recurrence and thus patients who will benefit from adjuvant therapy can be determined.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The effect of scoring systems for predicting locoregional recurrence in patients with differentiated thyroid cancerDifferentiated thyroid cancer constitutes approximately 90% of all thyroid tumors. Despite the excellent prognosis in the majority of patients, recurrence rates remain high. Although many scoring systems (TNM, AMES, MACIS etc) have been described to predict the prognosis, there is lack of scoring systems related to recurrence. We aimed to analyse the effect of scoring systems in predicting the recurrences rates. We retrospectively reviewed 106 patients with differentiated thyroid cancer. The patients were divided into risk groups, based on MACIS and MSKCC scoring system. The predictive value of the scoring system for assessing the recurrence rates were calculated. The rate of papillary, folicular and hurthle cell cancer were 82%, 10.4 % and 7.6% respectively. During a 35-month followup period, 16 patients were diagnosed with the locoregional recurrence. With MACIS scoring sytems, the locoregional recurrence rates were 9.1%, 42.9%, 50% and 42.9% for stage I, II, III and IV respectively. MSKCC calculated the recurrence risks as 4%, 20.9% and 38.5 for low, median and high risk, respectively. The most important factors for locoregionel recurrence were tumor size and extracapsular invasion. Scoring systems may be helpful in predicting locoregional recurrence and thus patients who will benefit from adjuvant therapy can be determined.

Özet

Diferansiye tiroid kanserleri tüm tiroid kanserlerinin yaklaşık %90'ını oluşturmaktadır. Hastaların büyük çoğunluğunda prognoz mükemmel olmasına rağmen, nüks riski halen yüksektir. Sağkalım analizleri için birçok skorlama sistemi (TNM, AMES, MACIS gibi) tanımlanmasına rağmen, rekürrens tahmini için skorlama sistemlerinin eksikliği hissedilmektedir. Bu çalışmada, sağkalım tahmininde kullanılan skorlama sistemlerinin, nüks oranlarını öngörü değerini analiz etmeyi amaçladık. Diferansiye tiroid kanseri tanısıyla tedavi edilmiş 106 hastanın verileri retrospektif incelendi.Hastalar MACIS ve MSKCC skorlama sistemi esas alınarak risk gruplarına ayrıldı.Skorlama sistemlerinin nüks oranlarını doğru olarak tahmin gücü hesaplandı. Papiller, foliküler ve hürthle hücreli kanser oranları sırasıyla, %82, %10.4 ve %7.6idi. Ortalama 35 aylık takip sonunda 16 hastada lokorejyonel nüks saptandı. MACIS skorlama sistemi ile lokorejyonel nüks oranları evre I, II, III ve IV için sırasıyla %9.1, %42.9, % 50 ve %42.9 olarak hesaplandı. MSKCC sistemi ise nüks oranını, düşük, orta ve yüksek riskli grup için sırasıyla %4, %20.9 ve %38.5 olarak hesapladı. Lokorejyonel nüks için en önemli faktörler olarak tümör boyutu ve ekstrakapsüler invazyon durumu ön plana çıktı. Skorlama sistemleri ve prognostik faktörler lokorejyonel nüksü öngörmede yardımcı olmakta ve böylece adjuvan tedaviden fayda görecek yüksek riskli hastalar belirlenebilmektedir.

🔖

Cite This Article

ÖZDEMİR, B., KILBAŞ, Z., YİĞİT, T., KOZAK, O., MENTEŞ, Ö., ARSLAN, İ. (2014). The effect of scoring systems for predicting locoregional recurrence in patients with differentiated thyroid cancer. Gülhane Tıp Dergisi, Cilt: 56 - Sayı: 3, 138–142. https://ajindex.com/articles/213677

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Holler T, Theriault J, Payne RJ, Clark J, Eski S, and Freeman JL. Prognostic Factors in Patients with Multiple Recurrences of Well-Differentiated Thyroid Carcinoma. J Oncol 2009;2009: 650340
  2. Lundgren CI, Hall P, Ekbom A, Frisell J, Zedenius J, Dickman PW. Incidence and survival of Swedish patients with differentiated thyroid cancer. Int J Cancer 2003;106: 569 -573
  3. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990;19: 545-576
  4. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114: 1050 -1058
  5. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97: 418 - 428
  6. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80: 1803-1804
  7. Shaha, AR Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer Laryngoscope 2004;114: 393-402
  8. Gulcelık MA, Gulcelık NE, Kuru B, Camlıbel M, Alagol H. Prognostic Factors Determining Survival in Differentiated Thyroid Cancer. Journal Of Surgical Oncology 2007;96: 598- 604 9. Hundahl SA Fleming ID Fremgen AM A National Cancer Data Base Report on 53,856 Cases of Thyroid Carcinoma Treated in the US, 1985-1995. Cancer 1998; 83: 2638-2648. 10.Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995;118: 1131
  9. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91: 313
  10. Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract 2008;14: 764
  11. Ward LS, Souza SL, Assumpcao LV. The impact of nodal metastases on prognosis of well-differentiated thyroid cancer suggests the practice of prophylactic neck dissection. Arch Otolaryngol Head Neck Surg 2003;129: 495 - 496 14. American College of Endocrinology, AACE/AAES Medi- cal/Surgical Guidelines for Clinical Practice, Management of Thyroid Carcinoma, American Association of Clinical Endocrinologists, Endocrine Practice 2001;7: 202-220
  12. DeGroot, LJ, Kaplan, E.L., Straus, F.H.